06/2021. MV130/MV140 in infections under immunosuppressive treatment

An original research on the preventive effect of MV130 (Bactek) and MV140 (Uromune) on infections associated with immunosuppressant treatment in patients with systemic autoimmune diseases has been published in Frontiers in Immunology

MV130 (Bactek) and MV140 (Uromune) are sublingual polybacterial vaccines (INMUNOTEK) composed of different inactivated whole bacteria, designed to prevent a broad spectrum of respiratory and urinary tract infections, respectively.

Systemic autoimmune diseases require immunosuppressive drug treatments to control the autoimmune disease. These treatments have as adverse effects an increase in respiratory and urinary tract infections by different pathogens.

This study shows a very significant decrease in the frequency of such infections in patients treated with MV130 or MV140 despite the immunosuppressive treatment of their underlying disease. This is associated with a decrease in the use of antibiotics, unscheduled hospital visits, and number of hospitalizations in these patients.

This research has been carried out at the Rheumatology and Clinical Immunology departments of the Hospital Clínico San Carlos of Madrid with the collaboration of INMUNOTEK.